Education
About Us
Working with TipRanks
Follow Us
PDS Biotechnology Corporation (PDSB)
NASDAQ:PDSB
PDSB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $4.42
Previous CloseN/A
Volume197.50K
Average Volume (3M)643.58K
Market Cap
$46.76M
Enterprise Value$41.75M
Total Cash (Recent Filing)$130.19M
Total Debt (Recent Filing)$5.30M
Price to Earnings (P/E)―
Beta2.45
Next Earnings
May 14, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding45,395,850
10 Day Avg. Volume315,459
30 Day Avg. Volume643,576
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$8.75Price Target Upside749.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
PDS Biotechnology News
PremiumCompany Announcements
PDS Biotechnology Advances Cancer Immunotherapy Trials
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of the Phase 3 VERSATILE-003 study marks a pivotal step in evaluating the safety and efficacy of Versamune HPV in combination with pembrolizumab for a specific type of cancer.
Regulatory ApprovalThe FDA's acceptance of the IND application to assess Versamune-MUC1 in combination with PDS01ADC opens new avenues for treating MUC1-positive unresectable, metastatic colorectal carcinoma.
Scientific AdvancementsResults from the VERSATILE-002 study demonstrate a clear clinical benefit, particularly in terms of objective response rate and survival metrics, suggesting a promising future for HPV targeted immunotherapy.
Bears Say
Financial ConcernsExploration of additional funding avenues highlights potential financial challenges that could impact the completion of ongoing operations.
Funding ChallengesThe company expressed a need to explore additional funding opportunities to complete select ongoing operations, including the VERSATILE-003 trial.
---
Ownership Overview
1.34% Insiders
4.46% Mutual Funds
0.74% Other Institutional Investors
89.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PDSB FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was $0.85 and its highest was $4.42 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
PDS Biotechnology Corporation’s market cap is $46.76M.
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is May 14, 2025 which is in 29 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on Mar 27, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.277 by $0.067.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate is -0.22.
How many shares outstanding does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 45,395,850 shares outstanding.
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.277. Following the earnings report the stock price went up 0.806%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Currently, no hedge funds are holding shares in PDSB
---
PDS Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.75 (749.51% Upside)
$8.75 (749.51% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 117.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $50.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.43%
12-Months-Change
Fundamentals
Return on Equity
-166.65%
Trailing 12-Months
Asset Growth
-23.63%
Trailing 12-Months
Company Description
PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
---
PDSB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted several significant achievements, including the initiation of a pivotal Phase 3 trial and promising Phase 2 results, as well as successful fundraising efforts. However, challenges such as increased net interest expenses and the need for further capital to complete the trial were noted, indicating a balanced outlook.Read More>---
PDSB Stock 12 Month Forecast
Average Price Target
$8.75
▲(749.51% Upside)
Technical Analysis
Nektar Therapeutics
―
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Immunovant
―
Best Analysts Covering PDSB
1 Year
1 Year Success Rate
0/12 ratings generated profit
1 Year Average Return
-51.29%
reiterated a buy rating 18 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -51.29% per trade.
---